PMID- 32326763
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20210502
IS  - 1029-2470 (Electronic)
IS  - 1071-5762 (Print)
IS  - 1029-2470 (Linking)
VI  - 54
IP  - 5
DP  - 2020 May
TI  - Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 
      diabetic rat model.
PG  - 311-318
LID - 10.1080/10715762.2020.1754409 [doi]
AB  - This study sought to determine whether the addition of mitoquinone (Mito-Q) in 
      the diet is an effective treatment for peripheral neuropathy in animal models of 
      diet-induced obesity (pre-diabetes) and type 2 diabetes. Unlike other 
      anti-oxidative stress compounds investigated as a treatment for peripheral 
      neuropathy, Mito-Q specifically targets mitochondria. Although mito-Q has been 
      shown to reduce oxidative stress generated by mitochondria there have been no 
      studies performed of the effect of Mito-Q on peripheral neuropathy induced by 
      diet-induced obesity or type 2 diabetes. Diet-induced obese (12 weeks after high 
      fat diet) or type 2 diabetic rats (12 weeks of high fat diet and 4 weeks after 
      the onset of hyperglycemia) were treated via the diet with Mito-Q (0.93 g/kg 
      diet) for 12 weeks. Afterwards, glucose utilization, vascular reactivity of 
      epineurial arterioles to acetylcholine and peripheral neuropathy related 
      endpoints were examined. The addition of Mito-Q to the diets of obese and 
      diabetic rats improved motor and/or sensory nerve conduction velocity, cornea and 
      intraepidermal nerve fibre density, cornea sensitivity and thermal nociception. 
      Surprisingly, treating obese and diabetic rats with Mito-Q did not improve 
      glucose utilization or vascular reactivity by epineurial arterioles to 
      acetylcholine. These studies imply that mitochondrial dysfunction contributes to 
      peripheral neuropathy in animal models of pre-diabetes and late-stage type 2 
      diabetes. However, improvement in peripheral neuropathy following treatment with 
      Mito-Q was not associated with improvement in glucose utilization or vascular 
      reactivity of epineurial arterioles to acetylcholine.
FAU - Fink, Brian
AU  - Fink B
AD  - Department of Veterans Affairs, Iowa City Health Care System, Iowa City, IA, USA.
FAU - Coppey, Lawrence
AU  - Coppey L
AD  - Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
FAU - Davidson, Eric
AU  - Davidson E
AD  - Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
FAU - Shevalye, Hanna
AU  - Shevalye H
AD  - Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
FAU - Obrosov, Alexander
AU  - Obrosov A
AD  - Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
FAU - Chheda, Pratik Rajesh
AU  - Chheda PR
AD  - College of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Kerns, Robert
AU  - Kerns R
AD  - College of Pharmacy, University of Iowa, Iowa City, IA, USA.
FAU - Sivitz, William
AU  - Sivitz W
AD  - Department of Veterans Affairs, Iowa City Health Care System, Iowa City, IA, USA.
AD  - Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
AD  - Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa 
      City, IA, USA.
FAU - Yorek, Mark
AU  - Yorek M
AD  - Department of Veterans Affairs, Iowa City Health Care System, Iowa City, IA, USA.
AD  - Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
AD  - Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa 
      City, IA, USA.
AD  - Veterans Affairs Center for the Prevention and Treatment of Visual Loss, Iowa 
      City, IA, USA.
LA  - eng
GR  - I01 RX000889/RX/RRD VA/United States
GR  - R01 DK107399/DK/NIDDK NIH HHS/United States
GR  - R01 DK116624/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20200424
PL  - England
TA  - Free Radic Res
JT  - Free radical research
JID - 9423872
RN  - 0 (Antioxidants)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Organophosphorus Compounds)
RN  - 1339-63-5 (Ubiquinone)
RN  - 47BYS17IY0 (mitoquinone)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Diabetes Mellitus, Experimental/chemically induced/drug therapy
MH  - Diabetes Mellitus, Type 2/chemically induced/drug therapy
MH  - Diet, High-Fat/adverse effects
MH  - *Disease Models, Animal
MH  - Hypoglycemic Agents/*pharmacology
MH  - Male
MH  - Mitochondria/drug effects
MH  - Obesity/*drug therapy
MH  - Organophosphorus Compounds/*pharmacology
MH  - Peripheral Nervous System Diseases/chemically induced/drug therapy
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin
MH  - Ubiquinone/*analogs & derivatives/pharmacology
PMC - PMC7329571
MID - NIHMS1589171
OTO - NOTNLM
OT  - Peripheral neuropathy
OT  - diabetes
OT  - mitoquinone
OT  - obesity
OT  - oxidative stress
EDAT- 2020/04/25 06:00
MHDA- 2020/12/15 06:00
PMCR- 2021/05/01
CRDT- 2020/04/25 06:00
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2021/05/01 00:00 [pmc-release]
AID - 10.1080/10715762.2020.1754409 [doi]
PST - ppublish
SO  - Free Radic Res. 2020 May;54(5):311-318. doi: 10.1080/10715762.2020.1754409. Epub 
      2020 Apr 24.